<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05055323</url>
  </required_header>
  <id_info>
    <org_study_id>20F.041</org_study_id>
    <nct_id>NCT05055323</nct_id>
  </id_info>
  <brief_title>A Study to Determine if the Drug, Pyrvinium Pamoate, is Safe and Tolerable in Patients With Pancreatic Cancer</brief_title>
  <official_title>A Phase I Dose Escalation Study Using Pyrvinium Pamoate Targeting HuR in Pancreatic Ductal Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I trial studies the side effects and best dose of pyrvinium pamoate for the&#xD;
      treatment of pancreatic ductal adenocarcinoma that cannot be removed by surgery (resectable).&#xD;
      Pyrvinium pamoate may slow down tumor growth and help patients live longer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To determine the safety and tolerability of pyrvinium pamoate (PP), dosed orally, in&#xD;
      patients with pancreatic ductal adenocarcinoma (PDAC) that are surgical candidates.&#xD;
&#xD;
      SECONDARY OBJECTIVE:&#xD;
&#xD;
      I. Assessment of PP's pharmacokinetic and pharmacodynamic (PK/PD) profile and bioavailability&#xD;
      in humans.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study.&#xD;
&#xD;
      Patients receive pyrvinium pamoate orally (PO) once daily (QD) for 3 days in the absence of&#xD;
      disease progression or unacceptable toxicity. Patients then undergo standard of care surgery.&#xD;
&#xD;
      After completion of study treatment, patients are followed up for 30 days and then every week&#xD;
      for up to 4 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 29, 2021</start_date>
  <completion_date type="Anticipated">April 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of dose limited toxicity (DLT)</measure>
    <time_frame>Up to 30 days from last dose</time_frame>
    <description>Considered any grade 3 or higher adverse event due to the drug itself or delay of surgery. Research coordinator will call patient every day to monitor for DLTs.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Profile of pyrvinium pamoate (PP)</measure>
    <time_frame>At Start of Treatment</time_frame>
    <description>Will be assessed using liquid chromatography followed by mass spectrometry (LC/MS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Profile of pyrvinium pamoate (PP)</measure>
    <time_frame>Completion of treatment</time_frame>
    <description>Will be assessed using liquid chromatography followed by mass spectrometry (LC/MS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bioavailability of PP</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>Will be assessed using liquid chromatography followed by mass spectrometry (LC/MS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatty tissue accumulation of PP</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>Will be assessed using liquid chromatography followed by mass spectrometry (LC/MS).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Resectable Pancreatic Ductal Adenocarcinoma</condition>
  <condition>Stage 0 Pancreatic Cancer AJCC v8</condition>
  <condition>Stage I Pancreatic Cancer AJCC v8</condition>
  <condition>Stage IA Pancreatic Cancer AJCC v8</condition>
  <condition>Stage IB Pancreatic Cancer AJCC v8</condition>
  <condition>Stage II Pancreatic Cancer AJCC v8</condition>
  <condition>Stage IIA Pancreatic Cancer AJCC v8</condition>
  <condition>Stage IIB Pancreatic Cancer AJCC v8</condition>
  <arm_group>
    <arm_group_label>Treatment (pyrvinium pamoate)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive pyrvinium pamoate PO QD for 3 days in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyrvinium Pamoate</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (pyrvinium pamoate)</arm_group_label>
    <other_name>3546-41-6</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with pancreatic ductal adenocarcinoma (PDAC) who are deemed to be surgical&#xD;
             candidates by the Thomas Jefferson University surgery department. Patients will be&#xD;
             assessed by the pancreatic surgeons in the pancreatic surgery clinic, and if they are&#xD;
             found to have resectable disease, they can be considered for this study&#xD;
&#xD;
          -  Patients must not be on neoadjuvant therapy, or have received their last neoadjuvant&#xD;
             treatment greater than or equal to within three weeks of starting PP therapy&#xD;
&#xD;
          -  Provide signed and dated informed consent form&#xD;
&#xD;
          -  Willing to comply with all study procedures and be available for the duration of the&#xD;
             study&#xD;
&#xD;
          -  Patients must have an estimated life expectancy of &gt; 3 months, and Eastern Cooperative&#xD;
             Oncology Group (ECOG) performance status of 0-1&#xD;
&#xD;
          -  All patients regardless of age or gender must agree to observe proper contraceptive&#xD;
             methods as to avoid becoming pregnant or causing pregnancy for the duration of the&#xD;
             study (30 days after last dose of drug)&#xD;
&#xD;
               -  Males will practice safe sex methods (i.e. condoms)&#xD;
&#xD;
               -  Women of child bearing potential will practice safe sex methods (i.e. condoms,&#xD;
                  birth control), if a female on the study is of child-bearing age, they will have&#xD;
                  to take a urine human chorionic gonadotropin (HCG) (pregnancy) test prior to&#xD;
                  enrolling on the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with ongoing anticancer therapies, or those who will have received an&#xD;
             anticancer therapeutic &lt;3 weeks prior to the first dose of PP&#xD;
&#xD;
          -  Any condition that precludes pancreatic surgical resection at the time of the study&#xD;
&#xD;
          -  Pregnancy or currently breastfeeding&#xD;
&#xD;
          -  Known allergic reactions to components of the study product(s): pyrvinium pamoate/&#xD;
             pyrvinium embonate (Molevac)&#xD;
&#xD;
          -  Patients with chronic bowel conditions (such as irritable bowel syndrome [IBS])&#xD;
&#xD;
          -  Kidney function impairment (serum creatine &gt; 1.5 x ULN or creatine clearance &lt;/= 60&#xD;
             ml/1.73m^2 fr patients with creatine levels &gt; 1.5 x ULN).&#xD;
&#xD;
          -  Patients with liver function impairment: Alkaline phosphatase, ALT and AST above three&#xD;
             folds the normal limit (see normal ranges); Total Bilirubin level &gt; 3mg/dl; Albumin &lt;&#xD;
             3g/dl&#xD;
&#xD;
             * Alkaline phosphatase:&#xD;
&#xD;
               -  0-9 years (yr): 83-280 IU/L at 37 degrees Celsius&#xD;
&#xD;
               -  10-14 yr: 91-400&#xD;
&#xD;
               -  15-17 yr: 37-240&#xD;
&#xD;
               -  18-49 yr: 29-92&#xD;
&#xD;
               -  50-74 yr: 25-120&#xD;
&#xD;
               -  75-97 yr: 29-160&#xD;
&#xD;
               -  98-99 yr: 29-120&#xD;
&#xD;
               -  &gt; 99 yr: 29-160&#xD;
&#xD;
          -  Patients with liver function impairment outside of the below ranges&#xD;
&#xD;
             * Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]):&#xD;
&#xD;
             ** Male (M): 1-45 IU/L at 37 degrees Celsius&#xD;
&#xD;
             ** Female (F): 1-30&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]):&#xD;
&#xD;
               -  M: 7-42 IU/L at 37 degrees Celsius&#xD;
&#xD;
               -  F: 7-35&#xD;
&#xD;
          -  Patients with liver function impairment outside of the below ranges&#xD;
&#xD;
             * Albumin:&#xD;
&#xD;
               -  0-1 yr: 2.6-4.4&#xD;
&#xD;
               -  1-15 yr: 3.0-4.7&#xD;
&#xD;
               -  16-99 yr: 3.2-4.9&#xD;
&#xD;
          -  Patients with liver function impairment outside of the below ranges&#xD;
&#xD;
             * Bilirubin, total:&#xD;
&#xD;
             ** 0.1-0.9 mg/dL&#xD;
&#xD;
          -  Patients with liver function impairment outside of the below ranges * Protein, total:&#xD;
&#xD;
               -  0-1 yr: 4.6-7.2 g/dL&#xD;
&#xD;
               -  1-15 yr: 5.7-8.2&#xD;
&#xD;
               -  16-99 yr: 6.0-8.5&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Harish Lavu, MD</last_name>
    <phone>215-955-9402</phone>
    <email>Harish.Lavu@jefferson.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harish Lavu, MD</last_name>
      <phone>215-955-9402</phone>
      <email>Harish.Lavu@jefferson.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 6, 2021</study_first_submitted>
  <study_first_submitted_qc>September 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2021</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pyrvinium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

